178 related articles for article (PubMed ID: 37684711)
1. Effect of education regarding treatment guidelines for schizophrenia and depression on the treatment behavior of psychiatrists: A multicenter study.
Hasegawa N; Yasuda Y; Yasui-Furukori N; Yamada H; Hori H; Ichihashi K; Takaesu Y; Iida H; Muraoka H; Kodaka F; Iga JI; Hashimoto N; Ogasawara K; Ohi K; Fukumoto K; Numata S; Tsuboi T; Usami M; Hishimoto A; Furihata R; Kishimoto T; Nakamura T; Katsumoto E; Ochi S; Nagasawa T; Atake K; Kubota C; Komatsu H; Yamagata H; Ide K; Takeshima M; Kido M; Kikuchi S; Okada T; Matsumoto J; Miura K; Shimazu T; Inada K; Watanabe K; Hashimoto R
Psychiatry Clin Neurosci; 2023 Oct; 77(10):559-568. PubMed ID: 37684711
[TBL] [Abstract][Full Text] [Related]
2. The effect of education regarding treatment guidelines for schizophrenia and major depressive disorders on psychiatrists' hypnotic medication prescribing behavior: a multicenter study.
Nakamura T; Furihata R; Hasegawa N; Kodaka F; Muraoka H; Ichihashi K; Ochi S; Numata S; Tsuboi T; Makinodan M; Iida H; Onitsuka T; Kashiwagi H; Takeshima M; Hashimoto N; Nagasawa T; Usami M; Yamagata H; Takaesu Y; Miura K; Matsumoto J; Ohi K; Yamada H; Hori H; Inada K; Watanabe K; Hashimoto R; Yasui-Furukori N
BMC Psychiatry; 2024 May; 24(1):399. PubMed ID: 38807065
[TBL] [Abstract][Full Text] [Related]
3. Improvement of psychiatrists' clinical knowledge of the treatment guidelines for schizophrenia and major depressive disorders using the 'Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)' project: A nationwide dissemination, education, and evaluation study.
Takaesu Y; Watanabe K; Numata S; Iwata M; Kudo N; Oishi S; Takizawa T; Nemoto K; Yasuda Y; Tagata H; Tsuboi T; Tsujino N; Hashimoto N; Matsui Y; Hori H; Yamamori H; Sugiyama N; Suwa T; Kishimoto T; Hishimoto A; Usami M; Furihata R; Iwamoto K; Fujishiro H; Nakamura T; Mizuno K; Inagaki T; Katsumoto E; Tomita H; Ohi K; Muraoka H; Atake K; Iida H; Nagasawa T; Fujita J; Yamamura S; Onitsuka T; Murata A; Takayanagi Y; Noda H; Matsumura Y; Takezawa K; Iga JI; Ichihashi K; Ogasawara K; Yamada H; Inada K; Hashimoto R
Psychiatry Clin Neurosci; 2019 Oct; 73(10):642-648. PubMed ID: 31437336
[TBL] [Abstract][Full Text] [Related]
4. A dissemination and education programme to improve the clinical behaviours of psychiatrists in accordance with treatment guidelines for schizophrenia and major depressive disorders: the Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE) project.
Yamada H; Motoyama M; Hasegawa N; Miura K; Matsumoto J; Ohi K; Yasui-Furukori N; Numata S; Takeshima M; Sugiyama N; Nagasawa T; Kubota C; Atake K; Tsuboi T; Ichihashi K; Hashimoto N; Inagaki T; Takaesu Y; Iga JI; Hori H; Onitsuka T; Komatsu H; Hishimoto A; Fukumoto K; Fujimoto M; Nakamura T; Nemoto K; Furihata R; Yamamura S; Yamagata H; Ogasawara K; Katsumoto E; Murata A; Iida H; Ochi S; Makinodan M; Kido M; Kishimoto T; Yasuda Y; Usami M; Suwa T; Inada K; Watanabe K; Hashimoto R
BJPsych Open; 2022 Apr; 8(3):e83. PubMed ID: 35446248
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of discharge prescriptions for patients with schizophrenia or major depressive disorder: Real-world evidence from the Effectiveness of Guidelines for Dissemination and Education (EGUIDE) psychiatric treatment project.
Hashimoto N; Yasui-Furukori N; Hasegawa N; Ishikawa S; Numata S; Hori H; Iida H; Ichihashi K; Furihata R; Murata A; Tsuboi T; Takeshima M; Kyou Y; Komatsu H; Kubota C; Ochi S; Takaesu Y; Usami M; Nagasawa T; Hishimoto A; Miura K; Matsumoto J; Ohi K; Yamada H; Inada K; Watanabe K; Shimoda K; Hashimoto R
Asian J Psychiatr; 2021 Sep; 63():102744. PubMed ID: 34325252
[TBL] [Abstract][Full Text] [Related]
6. Prescription patterns in patients with schizophrenia in Japan: First-quality indicator data from the survey of "Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE)" project.
Ichihashi K; Hori H; Hasegawa N; Yasuda Y; Yamamoto T; Tsuboi T; Iwamoto K; Kishimoto T; Horai T; Yamada H; Sugiyama N; Nakamura T; Tsujino N; Nemoto K; Oishi S; Usami M; Katsumoto E; Yamamori H; Tomita H; Suwa T; Furihata R; Inagaki T; Fujita J; Onitsuka T; Miura K; Matsumoto J; Ohi K; Matsui Y; Takaesu Y; Hashimoto N; Iga J; Ogasawara K; Yamada H; Watanabe K; Inada K; Hashimoto R
Neuropsychopharmacol Rep; 2020 Sep; 40(3):281-286. PubMed ID: 32602667
[TBL] [Abstract][Full Text] [Related]
7. The characteristics of patients receiving psychotropic pro re nata medication at discharge for the treatment of schizophrenia and major depressive disorder: A nationwide survey from the EGUIDE project.
Ichihashi K; Kyou Y; Hasegawa N; Yasui-Furukori N; Shimizu Y; Hori H; Hashimoto N; Ide K; Imamura Y; Yamada H; Ochi S; Iga JI; Takaesu Y; Ohi K; Tsuboi T; Iida H; Yamagata H; Hishimoto A; Horai T; Usami M; Makinodan M; Nagasawa T; Komatsu H; Kido M; Muraoka H; Atake K; Takeshima M; Kubota C; Inagaki T; Tamai S; Kishimoto T; Furihata R; Matsumoto J; Miura K; Inada K; Watanabe K; Kasai K; Hashimoto R
Asian J Psychiatr; 2022 Mar; 69():103007. PubMed ID: 35051727
[TBL] [Abstract][Full Text] [Related]
8. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
[TBL] [Abstract][Full Text] [Related]
9. The characteristics of discharge prescriptions including pro re nata psychotropic medications for patients with schizophrenia and major depressive disorder from the survey of the "Effectiveness of guidelines for dissemination and education in psychiatric treatment (EGUIDE)" project.
Kyou Y; Yasui-Furukori N; Hasegawa N; Ide K; Ichihashi K; Hashimoto N; Hori H; Shimizu Y; Imamura Y; Muraoka H; Iida H; Ohi K; Yasuda Y; Ogasawara K; Numata S; Iga JI; Tsuboi T; Ochi S; Kodaka F; Furihata R; Onitsuka T; Makinodan M; Komatsu H; Takeshima M; Kubota C; Hishimoto A; Atake K; Yamagata H; Kido M; Nagasawa T; Usami M; Kishimoto T; Kikuchi S; Matsumoto J; Miura K; Yamada H; Watanabe K; Inada K; Hahimoto R
Ann Gen Psychiatry; 2022 Dec; 21(1):52. PubMed ID: 36567327
[TBL] [Abstract][Full Text] [Related]
10. Hypnotic medication use among inpatients with schizophrenia and major depressive disorder: results of a nationwide study.
Furihata R; Otsuki R; Hasegawa N; Tsuboi T; Numata S; Yasui-Furukori N; Kashiwagi H; Hori H; Ochi S; Muraoka H; Onitsuka T; Komatsu H; Takeshima M; Hishimoto A; Nagasawa T; Takaesu Y; Nakamura T; Asami T; Miura K; Matsumoto J; Ohi K; Yasuda Y; Iida H; Ogasawara K; Hashimoto N; Ichihashi K; Yamada H; Watanabe K; Inada K; Hashimoto R
Sleep Med; 2022 Jan; 89():23-30. PubMed ID: 34875519
[TBL] [Abstract][Full Text] [Related]
11. Satisfaction with web-based courses on clinical practice guidelines for psychiatrists: Findings from the "Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)" project.
Iida H; Okada T; Nemoto K; Hasegawa N; Numata S; Ogasawara K; Miura K; Matsumoto J; Hori H; Iga JI; Ichihashi K; Hashimoto N; Yamada H; Ohi K; Yasui-Furukori N; Fukumoto K; Tsuboi T; Usami M; Furihata R; Takaesu Y; Hishimoto A; Muraoka H; Katsumoto E; Nagasawa T; Ochi S; Komatsu H; Kikuchi S; Takeshima M; Onitsuka T; Tamai S; Kubota C; Inada K; Watanabe K; Kawasaki H; Hashimoto R
Neuropsychopharmacol Rep; 2023 Mar; 43(1):23-32. PubMed ID: 36444167
[TBL] [Abstract][Full Text] [Related]
12. Change of prescription for patients with schizophrenia or major depressive disorder during admission: real-world prescribing surveys from the effectiveness of guidelines for dissemination and education psychiatric treatment project.
Hashimoto N; Yasui-Furukori N; Hasegawa N; Ishikawa S; Hori H; Iida H; Ichihashi K; Miura K; Matsumoto J; Numata S; Kodaka F; Furihata R; Ohi K; Ogasawara K; Iga JI; Muraoka H; Komatsu H; Takeshima M; Atake K; Kido M; Nakamura T; Kishimoto T; Hishimoto A; Onitsuka T; Okada T; Ochi S; Nagasawa T; Makinodan M; Yamada H; Tsuboi T; Yamada H; Inada K; Watanabe K; Hashimoto R
BMC Psychiatry; 2023 Jun; 23(1):473. PubMed ID: 37380997
[TBL] [Abstract][Full Text] [Related]
13. Improvements in the degree of understanding the treatment guidelines for schizophrenia and major depressive disorder in a nationwide dissemination and implementation study.
Numata S; Nakataki M; Hasegawa N; Takaesu Y; Takeshima M; Onitsuka T; Nakamura T; Edagawa R; Edo H; Miura K; Matsumoto J; Yasui-Furukori N; Kishimoto T; Hori H; Tsuboi T; Yasuda Y; Furihata R; Muraoka H; Ochi S; Nagasawa T; Kyou Y; Murata A; Katsumoto E; Ohi K; Hishimoto A; Inada K; Watanabe K; Hashimoto R
Neuropsychopharmacol Rep; 2021 Jun; 41(2):199-206. PubMed ID: 33704931
[TBL] [Abstract][Full Text] [Related]
14. National trends in psychotropic medication polypharmacy in office-based psychiatry.
Mojtabai R; Olfson M
Arch Gen Psychiatry; 2010 Jan; 67(1):26-36. PubMed ID: 20048220
[TBL] [Abstract][Full Text] [Related]
15. Prescription of potentially inappropriate psychotropic drugs in homeless people with schizophrenia and bipolar disorders. Results from the French Housing First (FHF) program.
Fond G; Tinland A; Boucekine M; Girard V; Loubière S; Auquier P; Boyer L;
Prog Neuropsychopharmacol Biol Psychiatry; 2019 Mar; 89():84-89. PubMed ID: 30153497
[TBL] [Abstract][Full Text] [Related]
16. [Impact of therapeutic advice on prescription of psychotropics for patients with serious mental illness].
Lebas E; Clerc B; Mangavelle J; Megard R; Franck N
Encephale; 2019 Sep; 45(4):304-311. PubMed ID: 30902340
[TBL] [Abstract][Full Text] [Related]
17. Clozapine Treatment Is Associated With Higher Prescription Rate of Antipsychotic Monotherapy and Lower Prescription Rate of Other Concomitant Psychotropics: A Real-World Nationwide Study.
Ochi S; Tagata H; Hasegawa N; Yasui-Furukori N; Iga JI; Kashiwagi H; Kodaka F; Komatsu H; Tsuboi T; Tokutani A; Numata S; Ichihashi K; Onitsuka T; Muraoka H; Iida H; Ohi K; Atake K; Kishimoto T; Hori H; Takaesu Y; Takeshima M; Usami M; Makinodan M; Hashimoto N; Fujimoto M; Furihata R; Nagasawa T; Yamada H; Matsumoto J; Miura K; Kido M; Hishimoto A; Ueno SI; Watanabe K; Inada K; Hashimoto R
Int J Neuropsychopharmacol; 2022 Oct; 25(10):818-826. PubMed ID: 35723038
[TBL] [Abstract][Full Text] [Related]
18. Psychiatrists' psychotropic drug prescription preferences for themselves or their family members.
Latas M; Stojkovic T; Ralic T; Milovanovic S; Jasovic-Gasic M
Psychiatr Danub; 2012 Jun; 24(2):182-7. PubMed ID: 22706417
[TBL] [Abstract][Full Text] [Related]
19. [Psychiatrists' decision making and monitoring of antipsychotic prescription for elderly schizophrenia patients].
Jalenques I; Ortega V; Legrand G; Auclair C
Encephale; 2016 Apr; 42(2):124-9. PubMed ID: 26796558
[TBL] [Abstract][Full Text] [Related]
20. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
Yıldız M; Osman E
Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
